MAPT and Alzheimer disease: Some studies have started to adopt plasma biomarkers, such as Aβ40, Aβ42, P-Tau, and pro-inflammatory cytokines, as additional means to track AD progression (NCT03533257, NCT04228666, NCT04570644) [235–237], and we expect this trend to continue.